BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35837183)

  • 21. Two-institution results of Stereotactic Body Radiation Therapy (SBRT) for treating adrenal gland metastases from liver cancer.
    Xu B; Zhao X; Chen D; Zhao W; Wang X; Ding C; Yuan Z; Zhang H
    BMC Cancer; 2023 Jan; 23(1):73. PubMed ID: 36681809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study.
    Comito T; Cozzi L; Zerbi A; Franzese C; Clerici E; Tozzi A; Iftode C; Navarria P; D'Agostino G; Fogliata A; Mancosu P; Tomatis S; Carnaghi C; Personeni N; Santoro A; Scorsetti M
    Eur J Surg Oncol; 2017 Apr; 43(4):735-742. PubMed ID: 28131670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
    Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
    BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi-agent chemotherapy.
    Hill C; Sehgal S; Fu W; Hu C; Reddy A; Thompson E; Hacker-Prietz A; Le D; De Jesus-Acosta A; Lee V; Zheng L; Laheru DA; Burns W; Weiss M; Wolfgang C; He J; Herman JM; Meyer J; Narang A
    Cancer Med; 2022 Apr; 11(7):1659-1668. PubMed ID: 35142085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stereotactic body radiotherapy for distant metastases to the head and neck.
    Mutsaers A; Abugharib A; Poon I; Loblaw J; Bayley A; Zhang L; Chin L; Galapin M; Erler D; Sahgal A; Higgins K; Enepekides D; Eskander A; Karam I
    Support Care Cancer; 2024 Mar; 32(4):230. PubMed ID: 38488881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma.
    Simoni N; Micera R; Paiella S; Guariglia S; Zivelonghi E; Malleo G; Rossi G; Addari L; Giuliani T; Pollini T; Cavedon C; Salvia R; Milella M; Bassi C; Mazzarotto R
    Clin Oncol (R Coll Radiol); 2021 Jan; 33(1):e31-e38. PubMed ID: 32682686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ten-Year Outcomes of Stereotactic Body Radiotherapy for Oligometastatic Breast Cancer: Does Synchronous Oligometastatic Breast Cancer Benefit?
    Nagpal SK; Khabra K; Ross G; Kirby AM
    Clin Oncol (R Coll Radiol); 2023 Nov; 35(11):736-743. PubMed ID: 37684189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase 1 Dose Escalation Study of SBRT Using 3 Fractions for Locally Advanced Pancreatic Cancer.
    Reyngold M; Karam SD; Hajj C; Wu AJ; Cuaron J; Lobaugh S; Yorke ED; Dickinson S; Jones B; Vinogradskiy Y; Shukla-Dave A; Do RKG; Sigel C; Zhang Z; Crane CH; Goodman KA
    Int J Radiat Oncol Biol Phys; 2023 Sep; 117(1):53-63. PubMed ID: 36918130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Consolidatory ablative stereotactic body radiation therapy after induction chemotherapy for unresectable pancreatic cancer: A single center experience.
    Lee HI; Kang HC; Chie EK
    Front Oncol; 2022; 12():974454. PubMed ID: 36505838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early outcomes of MR-guided SBRT for patients with recurrent pancreatic adenocarcinoma.
    Poiset SJ; Shah S; Cappelli L; Anné P; Mooney KE; Werner-Wasik M; Laufer TS; Posey JA; Lin D; Basu Mallick A; Lavu H; Bashir B; Yeo CJ; Mueller AC
    Radiat Oncol; 2024 May; 19(1):65. PubMed ID: 38812040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pulmonary oligometastases treated by stereotactic body radiation therapy (SBRT): a single institution's experience.
    Chai G; Yin Y; Zhou X; Hu Q; Lv B; Li Z; Shi M; Zhao L
    Transl Lung Cancer Res; 2020 Aug; 9(4):1496-1506. PubMed ID: 32953521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Re-Irradiation With Stereotactic Body Radiotherapy for In-Field Recurrence of Pancreatic Cancer After Prior Stereotactic Body Radiotherapy: Analysis of 24 Consecutive Cases.
    Shen Y; Zhu X; Cao F; Xie H; Ju X; Cao Y; Qing S; Jia Z; Gu L; Fang F; Zhang H
    Front Oncol; 2021; 11():729490. PubMed ID: 34796108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The RSSearch™ Registry: patterns of care and outcomes research on patients treated with stereotactic radiosurgery and stereotactic body radiotherapy.
    Davis JN; Medbery C; Sharma S; Danish A; Mahadevan A
    Radiat Oncol; 2013 Nov; 8():275. PubMed ID: 24274599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Local control and survival after stereotactic body radiation therapy of early-stage lung cancer patients in Slovenia.
    Stanic K; But-Hadzic J; Zagar J; Vrankar M
    Radiol Oncol; 2023 Sep; 57(3):389-396. PubMed ID: 37494591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of stereotactic body radiation therapy for locoregional recurrent pancreatic cancer after radical resection.
    Ji X; Zhou B; Ding W; Wang J; Jiang W; Li Y; Hu J; Sun X
    Front Oncol; 2022; 12():925043. PubMed ID: 35936670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
    Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biologically effective dose (BED) of stereotactic body radiation therapy (SBRT) was an important factor of therapeutic efficacy in patients with hepatocellular carcinoma (≤5 cm).
    Sun J; Zhang T; Wang J; Li W; Zhang A; He W; Zhang D; Li D; Ding J; Duan X
    BMC Cancer; 2019 Aug; 19(1):846. PubMed ID: 31455251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can STEreotactic Body Radiation Therapy (SBRT) Improve the Prognosis of Unresectable Locally Advanced Pancreatic Cancer? Long-Term Clinical Outcomes, Toxicity and Prognostic Factors on 142 Patients (STEP Study).
    Comito T; Massaro M; Teriaca MA; Franzese C; Franceschini D; Navarria P; Clerici E; Di Cristina L; Bertolini A; Tomatis S; Reggiori G; Bresolin A; Bozzarelli S; Rimassa L; Bonifacio C; Carrara S; Santoro A; Zerbi A; Scorsetti M
    Curr Oncol; 2023 Jul; 30(7):7073-7088. PubMed ID: 37504373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stereotactic Body Radiotherapy as an Effective Treatment for Pancreatic Cancer.
    Hurmuz P; Cengiz M; Ozyigit G; Yuce Sari S; Kahvecioglu A; Beduk Esen CS; Yalcin S; Zorlu F
    Cureus; 2023 Apr; 15(4):e38255. PubMed ID: 37252548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment.
    Fuller DB; Wurzer J; Shirazi R; Bridge SS; Law J; Mardirossian G
    Pract Radiat Oncol; 2015; 5(6):e615-23. PubMed ID: 26059509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.